Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rFIXFc Long-Term Safety in Hemophilia B (China Extension)
CTR20150426Phase 3Active
- Sponsor
- Biogen
- Start
- Jul 2015
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of eftrenonacog alfa in hemophilia B (HB), sponsored by Biogen. Started Jul 2015; status: active.
02
Drugs
eftrenonacog alfa
03
Conditions
hemophilia B (HB)
Beyond the preview
Go deeper on CTR20150426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20150426.